ATOS

Hardware Security Modules Market worth $2.0 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, September 23, 2022

The key factors contributing to the growth of the Hardware security module market include the requirement for effective management of cryptographic keys, and the need to follow stringent data security compliances are among the factors driving the growth of the Hardware security module market.

Key Points: 
  • The key factors contributing to the growth of the Hardware security module market include the requirement for effective management of cryptographic keys, and the need to follow stringent data security compliances are among the factors driving the growth of the Hardware security module market.
  • Secure Socket Layer (SSL) and Transport Layer Security (TLS) are cryptographic protocols that provide communications security over a computer network.
  • Hardware security modules help protect master SSL encryption keys, ensuring the overall integrity of the SSL process.
  • The significant presence of major companies offering cloud-based services in the hardware security modules market in this region for different verticals such as healthcare and IT & telecom also fuels market growth in North America.

Hardware Security Modules Market worth $2.0 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, September 23, 2022

The key factors contributing to the growth of the Hardware security module market include the requirement for effective management of cryptographic keys, and the need to follow stringent data security compliances are among the factors driving the growth of the Hardware security module market.

Key Points: 
  • The key factors contributing to the growth of the Hardware security module market include the requirement for effective management of cryptographic keys, and the need to follow stringent data security compliances are among the factors driving the growth of the Hardware security module market.
  • Secure Socket Layer (SSL) and Transport Layer Security (TLS) are cryptographic protocols that provide communications security over a computer network.
  • Hardware security modules help protect master SSL encryption keys, ensuring the overall integrity of the SSL process.
  • The significant presence of major companies offering cloud-based services in the hardware security modules market in this region for different verticals such as healthcare and IT & telecom also fuels market growth in North America.

Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference

Retrieved on: 
Wednesday, September 7, 2022

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24th Annual H.C. Wainwright Global Investment Conference being held on September 12 14, 2022 at the Lotte New York Palace.

Key Points: 
  • SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24th Annual H.C. Wainwright Global Investment Conference being held on September 12 14, 2022 at the Lotte New York Palace.
  • Mr. Guse will be available for one-on-one meetings.
  • To request a meeting and to register for the conference, click below:
    Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

Registration Now Open for Tribe Public’s Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022

Retrieved on: 
Monday, August 22, 2022

Once registered, Tribe members may then send their questions for Atossas management to [email protected] .

Key Points: 
  • Once registered, Tribe members may then send their questions for Atossas management to [email protected] .
  • Tribe members primarily include Institutions, Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media.
  • Tribe Members are encouraged to express their interest in speakers at the Tribe Public website via the Tribes FREE Wish List process.
  • Visit Tribe Publics Website http://www.tribepublic.com/ to join the Tribe and express your interests today.

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 8, 2022

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments.

Key Points: 
  • SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments.
  • The FDA has issued a clinical hold letter requesting additional information which Atossa plans to submit by the end of the third quarter 2022 and to initiate enrollment in the fourth quarter 2022.
  • For the quarter ended June 30, 2022, Atossa had no source of sustainable revenue and no associated cost of revenue.
  • Six Months Ended June 30, 2022 Financial Results (in thousands):
    For the six months ended June 30, 2022, Atossa had no source of sustainable revenue and no associated cost of revenue.

Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Retrieved on: 
Thursday, July 28, 2022

Part C of the study involved administering the two drugs in succession in healthy volunteers.

Key Points: 
  • Part C of the study involved administering the two drugs in succession in healthy volunteers.
  • The study originally included a Part D which was designed to assess the effects of the treatment regimen in hospitalized COVID-19 patients with moderate illness.
  • For example, radiation treatment can lead to radiation induced lung injury, which is poorly treated with current therapies and is often irreversible.
  • The Phase 1/2a study in Australia and other clinical studies must be successfully completed and regulatory approvals must be obtained before AT-H201 can be commercialized.

BillingPlatform Unveils New Product Innovations and Partner Connectors

Retrieved on: 
Wednesday, June 29, 2022

DENVER, June 29, 2022 /PRNewswire/ -- BillingPlatform, the revenue management solution for today's innovative business models, announced its latest platform and product innovations, including hosted payment pages as well as new and updated connectors to Salesforce, NetSuite, OneSource, Avalara and other enterprise systems. BillingPlatform continues to invest and extend the capabilities of its product portfolio to accelerate the quote-to-cash process and simplify revenue recognition for enterprises looking to optimize their billing and revenue management processes.

Key Points: 
  • BillingPlatform continues to invest and extend the capabilities of its product portfolio to accelerate the quote-to-cash process and simplify revenue recognition for enterprises looking to optimize their billing and revenue management processes.
  • BillingPlatform's latest product innovations include:
    Configure & Sell:The BillingPlatform CPQ product has been enhanced with greater rating precision, simplified quotation editing, the ability to generate renewals and additional flexibility when saving and sending quotes to customers.
  • Pay & Collect:Customers can now embed a payment page hosted by BillingPlatform to capture credit card and direct debit payments via the Adyen payment gateway enabling e-commerce billing.
  • In addition, BillingPlatform has enhanced several partner connectors including Salesforce, NetSuite, OneSource, Avalara and ATOS.

Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

Retrieved on: 
Thursday, June 2, 2022

Prior to joining Atossa, Mr. Butler spent 10 years at Exelixis, Inc. where he managed all communications from the preclinical through commercial stage for multiple drugs.

Key Points: 
  • Prior to joining Atossa, Mr. Butler spent 10 years at Exelixis, Inc. where he managed all communications from the preclinical through commercial stage for multiple drugs.
  • During his time at Exelixis, he was a part of the team that raised over $1B in equity and business development transactions.
  • While in London, he managed a 25+ person team, overseeing healthcare communications for the United Kingdom and Europe.
  • It will allow me to leverage my many years of experience across the communications spectrum in biotechnology.

Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

Retrieved on: 
Wednesday, May 18, 2022

SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that Kyle Guse, Chief Financial Officer and General Counsel, will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference.

Key Points: 
  • SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that Kyle Guse, Chief Financial Officer and General Counsel, will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference.
  • The conference is being held on May 23 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL.
  • Mr. Guse will be available for one-on-one meetings.
  • For more information, please visit www.atossatherapeutics.com .

Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 9, 2022

SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended March 31, 2022, and provides an update on recent company developments.

Key Points: 
  • SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended March 31, 2022, and provides an update on recent company developments.
  • The Company anticipates submitting an IND to the FDA in the second quarter of 2022.
  • For the quarter ended March 31, 2022, Atossa has no source of sustainable revenue and no associated cost of revenue.
  • Other compensation also increased $264 due to the addition of a new employee quarter over quarter as well as salary, bonus and benefit increases.